Risk-adapted use of intravesical immunotherapy

Journal article

Peer reviewed

Matthew R Braasch, Andreas Böhle and Michael A O'Donnell

BJU international, Vol.102(9 Pt B), pp.1254-1264

11/2008

DOI: 10.1111/j.1464-410X.2008.07968.x

PMID: 19035890

View Online

no abstract

Immunotherapy - methods

Neoplasm Recurrence, Local - prevention & control

Humans

Middle Aged

Risk Factors

Interferon-alpha - therapeutic use

Male

Antineoplastic Agents - therapeutic use

Clinical Trials as Topic

Urinary Bladder Neoplasms - drug therapy

Immunotherapy - adverse effects

Antineoplastic Agents - adverse effects

BCG Vaccine - adverse effects

Treatment Failure

Female

Aged

Interferon-alpha - adverse effects

Administration, Intravesical

BCG Vaccine - therapeutic use

Title: Subtitle: Risk-adapted use of intravesical immunotherapy
Creators: Matthew R Braasch - Department of Urology, University of Iowa, Iowa City, IA 52242-1089, USA
Andreas Böhle
Michael A O'Donnell
Resource Type: Journal article
Publication Details: BJU international, Vol.102(9 Pt B), pp.1254-1264
Publisher: England
DOI: 10.1111/j.1464-410X.2008.07968.x
PMID: 19035890
ISSN: 1464-4096
eISSN: 1464-410X
Language: English
Date published: 11/2008
Academic Unit: Urology
Record Identifier: 9984051561502771

23 Record Views